PT  - JOURNAL ARTICLE
AU  - Ige, Oluwafemi
AU  - Buru, Ayuba Sunday
AU  - Lamido, Tanko Zainab
AU  - Mohammed, Tahir
AU  - Dogara, Livingstone
AU  - Patience, Ijei Ifeoma
AU  - Halima, Bello-Manga
AU  - Reward, Audu
AU  - Samuel, Ige
AU  - Grace, Nmadu
TI  - Evaluation of SARS-CoV2 antibody Rapid Diagnostic Test kits (RDTs) and Real Time-Polymerase Chain Reaction (Rt-PCR) for COVID-19 Diagnosis in Kaduna, Nigeria
AID  - 10.1101/2020.11.24.20231324
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.24.20231324
4099  - http://medrxiv.org/content/early/2020/11/27/2020.11.24.20231324.short
4100  - http://medrxiv.org/content/early/2020/11/27/2020.11.24.20231324.full
AB  - The emergence of the RNA virus SARS-CoV2, the causative agent of COVID-19 and its declaration by the World Health Organization (WHO) as a pandemic has disrupted the delicate balance in health indices globally. Its attendant immune dysregulation and pathobiology is still evolving. Currently, real time PCR is the gold standard diagnostic test, however there are several invalidated antibody-based tests available for possible community screening. With ongoing community transmission in Nigeria, neither the true burden of COVID-19 nor the performance of these kits is presently known. This study therefore, compared the performance of the SARS CoV2 antibody test and the real time Polymerase Chain Reaction (Rt-PCR) in the diagnosis of COVID-19. For the purpose of this evaluation, we used the diagnostic test kit by Innovita® Biological Technology CO., LTD China, a total of 521 venous blood samples were collected from consenting patients for the SARS COVID-19 rapid diagnostic kit and Oral and Nasopharyngeal swabs were collected and analyzed using the real time Polymerase chain reaction technique for nucleic acid detection and quantification.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The approval for this research work was sought through the Honourable Commissioner of Health, Ministry of Health Kaduna State Nigeria,it was then formally approved by the Ministry of Health Kaduna State Research and Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are included in the manuscript as required.